Hormonal contraceptives have enabled millions of people globally to regulate menstrual cycles and plan reproduction. Like all medications, they involve benefits and drawbacks that require careful evaluation by patients and physicians. Although evidence shows clear advantages, researchers note that certain side effects such as mood changes or vascular events have received insufficient study. Multiple population analyses worldwide have identified a possible connection between these drugs and meningioma, an uncommon but generally manageable brain tumor. Danish Medicines Agency scientists examined twenty-five years of national health records involving approximately three million women to clarify this association. Results appear in JAMA Network Open. The investigation is the first large-scale effort to demonstrate that only particular contraceptive formulations correlate with meningioma development. The reported relative risk increase remains modest and absolute incidence stays low, yet further examination is warranted. Medroxyprogesterone injections exhibited the strongest link, raising relative risk roughly four times. Combined oral contraceptives and progestin-only pills showed weaker connections, elevating risk by about 1.5 times. These elevations occurred only during active use and typically resolved within five years after discontinuation. Cancer epidemiologist Paul Pharoah notes that while a fourfold relative increase appears substantial, lifetime meningioma risk affects roughly five women per thousand and rises only to six per thousand among users of medroxyprogesterone between ages twenty-five and forty-four. Such minor increments must be weighed against contraceptive benefits, and individuals should consult physicians before altering regimens. Meningiomas are uncommon and benign in approximately ninety percent of cases, though they occasionally produce seizures or cognitive difficulties and are managed through surgery or radiation. Numerous women have pursued legal action against the manufacturer of medroxyprogesterone injections since 2024. In late 2025 the US FDA added a warning label regarding possible meningioma association. Obstetrician Gino Pecoraro observes that while certain contraceptives carry a slight added risk, pregnancy itself involves documented hazards, with maternal mortality at 6.6 per hundred thousand in Australia compared to over ninety percent five-year survival after meningioma diagnosis. Although causes remain unclear, progesterone is suspected to contribute because women receive diagnoses more than twice as often as men, and tumors grow faster during pregnancy or progesterone-mimicking treatments. Reproductive endocrinologist Channa Jayasena states that high-dose progestogen exposure has been linked to meningioma for several years, noting that most tumors possess receptors responsive to the hormone, making a modest risk increase biologically plausible. Progestogens, synthetic progesterone analogs, appear in injections, intrauterine devices, combined pills, and mini-pills. Earlier research produced inconsistent findings on this potential connection.
